- Telehealth visits
- Insurance plan information
Bridget Keenan, MD, PhD
She | Her | Hers- Telehealth visits
- Insurance plan information
Bridget Keenan, MD, PhD
She | Her | Hers- Telehealth visits
- Insurance plan information
On this page
About me
Dr. Bridget Keenan is an oncologist and physician-scientist, a doctor particularly focused on research. She cares for patients with solid organ tumors who are seeking or enrolled in immunotherapy clinical trials (studies of promising new treatments). She has a special interest in digestive system cancers.
Keenan's research investigates various immunotherapy approaches to fighting cancer, including checkpoint inhibitors (drugs that prevent an immune system response that may otherwise allow cancer cells to evade destruction), cellular therapies, bispecific antibodies (parts of lab-produced antibodies that bind to T cells and tumors so that cancer cells are directly targeted) and other new treatments.
Keenan earned her medical degree and a doctorate in immunology at the Johns Hopkins University School of Medicine. At UCSF, she completed a residency in internal medicine and a fellowship in hematology and oncology.
Education & training
Board certification
- Medical Oncology, American Board of Internal Med/Medical Oncology
Fellowship
- Hematology - Oncology, University of California San Francisco - GME
Residency
- Internal Medicine, University of California San Francisco - GME
Internship
- Internal Medicine, University of California San Francisco - GME
Degree
- MD, Johns Hopkins University School of Medicine
Academic title
- Health Sciences Clinical Professor
Locations
My research
Clinical trials
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine CancersOpens in a new window
Recruiting
according to RECIST v 1.1 by investigator assessment from the date of treatment start until the earliest date of disease progression, death, or last evaluable...A Study of TAK-505 in Adults With Solid TumorsOpens in a new window
Recruiting
DLTs are defined as specific Grade 3 and 4 hematologic and hepatic nonhematologic events or any other Grade ≥3 adverse events related to treatment that occur d...
Publications
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.